At Mosaic Neuroscience, we believe that solving the hardest problems in neurodegenerative disease requires rethinking not just the science—but also the business model behind it.
That’s why Mosaic is structured as a Delaware Public Benefit Corporation (PBC), and why we’ve adopted a platform strategy inspired by high-growth infrastructure companies like ARM Holdings in semiconductors and Red Hat in open-source software. This isn’t charity—it’s a strategic choice designed to accelerate innovation, build durable competitive advantages, and unlock significant financial upside for mission-aligned investors.
A New Kind of Biotech Infrastructure Company
Mosaic is building the first platform for “Phase 0 clinical trials in vitro” for ALS and related disorders. Our platform enables early-stage virtual trials to predict which experimental drugs will work for which subgroups of patients before they reach the clinic—fundamentally improving drug-development speed, cost-efficiency, and success rates.
But to do this well, we need an ecosystem.
We’re creating shared scientific infrastructure: standardized models of disease, reference datasets, and interoperable tools that others can adopt, validate, and improve. Think of how ARM licenses a common chip architecture to phone manufacturers, allowing each to innovate without reinventing the wheel—or how Red Hat helps maintain and distribute the most stable, widely adopted version of Linux by sourcing the best improvements from a global community of developers.
Mosaic aims to do the same for preclinical neuroscience R&D.
- We define standards: reproducible cell models based on cryptic-exon splicing events in ALS.
- We convene the ecosystem: partner labs replicate and iterate on these models.
- We source and scale innovation: incorporating the best methods from across the ecosystem.
- We monetize: by licensing advanced models (e.g., Brainbow barcoded lines) and selling customized Phase 0 trial services to biotech partners.
The Mosaic Flywheel: How the Model Accelerates Itself
Our greatest competitive advantage is the data-driven flywheel created by the platform itself. Each new trial that runs on Mosaic generates high-resolution omics and drug-response data. That data reveals new biological insights—new targets, mechanisms, and subtypes—which in turn inspire the next wave of drug candidates to be tested on the platform.
More trials → more data → deeper insights → more validated targets → more promising drugs → more trials.
Every loop strengthens our predictive algorithms, enhances model fidelity, and grows the value of the platform’s aggregated knowledge base. The result is a self-reinforcing engine that compounds both scientific progress and commercial opportunity over time.
Why the Public Benefit Model Is Key to Our Growth
The PBC model helps make this ecosystem work. Unlike a traditional C corporation, a Delaware Public Benefit Corporation is a for-profit company that is legally required to consider both financial returns and a specific social or scientific mission—in our case, accelerating treatments for neurodegenerative disorders.
This doesn’t mean sacrificing returns. It means structuring our incentives so that profit and mission reinforce each other.
Every dollar we earn helps fund deeper scientific insight, higher-quality models, and more powerful tools—which in turn attract more customers, yield more data, and help us run even better trials. This positive feedback loop—our Mosaic Flywheel—is powered by reinvesting profits back into the research ecosystem.
Here’s how this model creates concrete business value:
1. Expands Access to Capital and Talent
Our PBC status opens doors to mission-aligned investors, nonprofits, and philanthropies that might not fund a traditional biotech. It also helps us recruit top scientific advisors by offering equity in a mission-driven enterprise.
2. Attracts and Retains Research Collaborators
Researchers are more willing to share models and data when they trust we’re not just extracting value. By funding cooperative research, we ensure enduring access to innovation.
3. Facilitates Biopharma Partnerships
Biopharma partners see Mosaic as neutral and mission-aligned, not a competitor. This builds trust and accelerates joint development.
4. Enables Cross-Sector Coordination
The PBC structure helps align academia, nonprofits, industry, and investors around a common goal—essential for translational science.
5. Drives Compounding Data Value
Because every project enriches the shared dataset, the network effects deepen: each trial improves prediction accuracy and platform attractiveness for the next.
Public Benefit Corporation vs. Traditional and Certified B Corporations
A Delaware Public Benefit Corporation (PBC) is a legal corporate form—a type of C corporation recognized under Delaware law that must pursue both profit and a specific public benefit. PBCs have fiduciary duties to balance shareholder value with mission impact, and they file periodic reports to demonstrate progress toward that mission.
By contrast, a Certified B Corporation (or “B Corp”) is not a legal structure but a third-party certification issued by the nonprofit B Lab. Any LLC or corporation can seek this certification by meeting B Lab’s standards for social and environmental performance. In short:
- PBC = legal status under Delaware law
- B Corp = voluntary certification by B Lab
- A company can be one, the other, or both.
Mosaic chose to incorporate as a Delaware PBC because it bakes our mission directly into our governance and investor obligations, ensuring that our pursuit of cures for neurodegenerative disease and our pursuit of profit remain permanently aligned.
If you’re an investor who shares our belief that the future of biotech lies in collaborative platforms, not siloed R&D, we’d love to connect.
Let’s build the infrastructure that accelerates cures.
—
Bernie Zipprich
CEO, Mosaic Neuroscience – A Public Benefit Corporation
bernie.zipprich@mosaicneuro.com
Mosaic Neuroscience 
Leave a comment